Slide 1: Diagnostics Biotech Company
Diagnostics Biotech Company NASDAQ: PRPO Founded in 2011 HQ: New Haven, CT DI S C L AI M E R T HIS PRESENT AT ION HAS BEE N PREPARE D B Y P RE CIPIO IN C. (T HE “C O MPAN Y”) AND IS GENERA L BA CKGROUND IN FOR MAT I ON ABOUT T HE C O MPAN Y’S ACT IV IT IES AS O F T HE DAT E O F T HIS PRESENT AT ION
Slide 2: Precipio milestones 2025
Precipio milestones 2025 +30% +275% Profitable Revenue growth Share price increase As of Q3-25 2
Slide 3: We develop products that save lives
We develop products that save lives Acute Myeloid Leukemia (AML) is one of the deadliest forms of cancer. Physicians treating patients with AML face two unsuitable options. Patient diagnosed with AML - Genetic tests ordered (10-15 day wait) OPTION Begin Standard Chemo; OPTION Wait 10-15 days for 1 (
Slide 4: Precipio is eliminating ineffective diagnosis
Precipio is eliminating ineffective diagnosis We eliminate both misdiagnosis and diagnostic delays, where outcomes depend on speed and accuracy. 25-40%* 10+ Days $100B** of blood cancer diagnoses generally accepted turnaround diagnostic errors cost US are incorrect times in molecular testing healthc
Slide 5: We've built an innovative product development platform, creating an unfair advantage
We’ve built an innovative product development platform, creating an unfair advantage Pathology Services Diagnostics Laboratory Products Division Our Unfair Advantage Unsolved diagnostic Facilities & equipment problems drive innovative We are the first customer of products every product we develop Ex
Slide 6: Our profitable clinical lab business fully funds R&D, significantly de-risking the company
Our profitable clinical lab business fully funds R&D, significantly de-risking the company Example: Clinical Lab Precipio’s ▪ Identifies market needs Product BCR-ABL1 ▪ Provides infrastructure Release assay and patient samples R&D Platform 1. Most advanced assay in market ▪ Leverages infrastructure
Slide 7: We deliver testing options not available before
We deliver testing options not available before Our products address the key challenges laboratories face: Staff shortage, Capital budgets, and the ability to deliver timely results Factor Competition Precipio Solution Impact Simplified workflow enables streamlined Workflow Complex Simple process, f
Slide 8: We scale through national distribution partner agreements already in place
We scale through national distribution partner agreements already in place Go-to-market efficiency through leading channel partners, with nationwide reach Hospital / Reference POL* Academic Lab * Physician-Owned Laboratory 8
Slide 9: Blood cancers are just the beginning: Expanding into a $40B+ market
Blood cancers are just the beginning: Expanding into a $40B+ market Our technology is platform-ready to expand beyond hematology into broader cancer and molecular testing. PRESENT: NEAR TERM: LONG TERM: Blood Cancer Genetics Cancer Genetics Molecular Diagnostics 2.5% blood TAM: $500M* TAM $6.7B** TA
Slide 10: Recurring revenue growth, high-margin outlook
Recurring revenue growth, high-margin outlook As we scale products and alter the revenue mix, gross margins increase dramatically. Path Services Revenue mix Products Gross Margin Analysis Products Path services Blended 100% 100% 80% 80% 60% 60% 40% 40% 20% 20% 0% 0% Current Short term Long term Curr
Slide 11: Where the Products business can go
Where the Products business can go Gradual increase in market share, alongside expansion into new fields of diagnostics can deliver significant growth Market penetration Blood cancers Market potential ($B) Cancer genetics Molecular diagnostics Segment TAM 30% Blood cancers $ 0.5 Cancer Genetics $ 6.
Slide 12: Proven leadership with deep clinical and commercial experience
Proven leadership with deep clinical and commercial experience Ilan Danieli CEO Dr. Ayman Mohamed CTO Zaki Sabet COO Ilan Danieli Dr. Ayman Mohamed Zaki Sabet CEO CTO COO Stephen Miller CCO Matt Gage CFO Miri Radomski CPO Legal Counsel Stephen Miller Miri Radomski Matt Gage CCO CPO & Legal CFO Couns
Slide 13: Precipio: A high-margin, proprietary diagnostics platform with massive upside
Precipio: A high-margin, proprietary diagnostics platform with massive upside Disruptive, Proprietary Products Rooted in solutions to 1 real-world diagnostic and monitoring challenges Unique Development Platform - rapid and 2 capital efficient Massive Market Opportunity – growing from 3 $0.5B TAM to
Slide 14: Thank you.
20250817 Thank you. Please contact us at investors@precipiodx.com